May 3, 2021
On April 16, 2021, the Institute for Clinical and Economic Review (ICER) released its final evidence report on two new treatments for lupus nephritis: Benlysta (manufactured by GlaxoSmithKline) and Lupkynis (Aurinia Pharmaceuticals). In the report, ICER claims to have...
Apr 23, 2021
After years of perpetually rising healthcare costs – not to mention a worldwide pandemic – many elected officials and policymakers – at both the state and federal level – are looking for ways to bring down the cost of public health programs. More and more often, these...
Apr 5, 2021
Last month, members of the Colorado General Assembly introduced a bill intended to lower prescription drug costs in the state. The legislation (Senate Bill 21-175) would create a Prescription Drug Affordability Review Board to set payment caps on drugs deemed to be...
Mar 17, 2021
On the March 2, 2021, the Institute for Clinical and Economic Review (ICER) released its final evidence report on three emerging treatments for high cholesterol patients: inclisiran (Novartis), bempedoic acid and bempedoic acid/ezetimibe (Esperion Therapeutics). Not...
Mar 5, 2021
By Robert Popovian & Wayne Winegarden March 1, 2021 President Joe Biden should take advantage of a bipartisan opportunity to meaningfully reduce patients’ out-of-pocket spending on biopharmaceuticals. Seizing this opportunity requires the president to recognize...
Mar 3, 2021
In September 2019, House Democrats introduced the Elijah R. Cummings Lower Drug Costs Now Act (H.R. 3), a bill designed to, among other things, bring down prescription drug costs in the Medicare Part D program. A few months later, the Congressional Budget Office (CBO)...
